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Abstract  
The benefit of regular physical activity and exercise training for the prevention of cardiovascular and 
metabolic diseases is undisputed. Many molecular mechanisms mediating exercise effects have been 
deciphered. Personalized exercise prescription can help patients in achieving their individual greatest 
benefit from an exercise-based cardiac rehabilitation programme. Yet, we still struggle to provide truly 
personalized exercise prescriptions to our patients.  
In this position paper, we address novel basic and translational research concepts that can help us 
understand the principles underlying the inter-individual differences in the response to exercise, and 
identify early on who would most likely benefit from which exercise intervention. This includes 
hereditary, non-hereditary and sex-specific concepts. Recent insights have helped us to take on a 
more holistic view, integrating exercise-mediated molecular mechanisms with those influenced by 
metabolism and immunity. Unfortunately, while the outline is recognizable, many details are still 
lacking to turn the understanding of a concept into a roadmap ready to be used in clinical routine. This 
position paper therefore also investigates perspectives on how ƚŚĞĂĚǀĞŶƚŽĨ ‘big dĂƚĂ ?and the use of 
animal models could help unravel inter-individual responses to exercise parameters and thus influence 
hypothesis building for translational research in exercise-based cardiac rehabilitation. 
 
 Introduction  
Epidemiological and interventional studies have demonstrated a benefit of regular physical activity 
and exercise for the prevention of cardiovascular and metabolic diseases.1 W4 Exercise acts in a 
pleiotropic manner, addressing cardiac contractile and diastolic properties, muscle anabolic and 
catabolic pathways, substrate metabolism, and regulatory processes governing tissue perfusion and 
energy storage.5,6 
While physiological research of the past decades allowed us to understand these principal 
interactions, crucial questions remain on how to effectively implement exercise interventions in 
clinical therapy. Access and compliance to CR programmes remains a critical factor in the success of 
an exercise intervention, which requires a highly motivated multi-disciplinary team.7 But basic and 
translational research can also help, addressing questions regarding the personalization of exercise 
prescription, in order to improve efficacy of exercise interventions throughout the 
cardio/vascular/metabolic continuum. Why do some patients not respond to exercise-based cardiac 
rehabilitation (CR), and how can we identify them early on? What drives the difference in response to 
CR in men and women? How is the response to exercise influenced by metabolism, immunity and 
their interaction?  
In addition to that, research methodology is rapidly advancing, bringing different views on translation 
of biochemical findings into the clinics. ,ŽǁǁŝůůƚŚĞĂĚǀĞŶƚŽĨ ‘big dĂƚĂ ?influence hypothesis building 
for translational research in CR? What is the sense and nonsense of using animal models in modern CR 
research? 
In this position paper, we aim to address these future challenges for basic and translational research in 
exercise-based CR. We critically review recent studies dealing with the most important yet 
unanswered questions in the field, both in preclinical and clinical research. Finally, we pinpoint gaps in 
current evidence that deserve intensified attention in future research. 
 
 Future targets and open questions in translational cardiac rehabilitation research 
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While exercise-based 
intervention 
programmes are 
recommended in 
primary and secondary 
cardiovascular 
prevention,8,9 it has 
also become clear that 
exercise parameters  W 
type, intensity, 
duration, frequency  W 
differentially address 
cardio-vascular and 
metabolic endpoints, 
and that the quality 
and quantity of the 
response differs 
significantly between 
participants. In 
addition to improving 
implementation, it is 
the personalization of 
exercise interventions 
that is an important 
focus of current and 
future research. 
2.1 Why do some 
patients not respond? 
The improvement in 
maximal aerobic capacity (peak oxygen uptake, VO2peak) following exercise-based CR is related to 
survival in a wide range of cardiovascular diseases, independent of other important risk factors.10 W12 
Even small increments in VO2peak result in substantially lower risk for all-cause and cause-specific 
mortality.3 Although trials that investigated the effects of exercise-based CR on exercise capacity have 
consistently shown favourable and clinically significant changes,13,14 a large variability is seen in the 
individual training response (relative change in VO2ƉĞĂŬĨŽůůŽǁŝŶŐƚƌĂŝŶŝŶŐ ?A?sK2peak). This variability 
exists both in healthy subjects and in patients with established cardiovascular disease, when exposed 
to similar exercise programs.12,15,16 Recent studies have shown that up to 33% of patients fail to 
demonstrate a meaningful increase in VO2peak in response to CR, despite adequate compliance to 
training ?dŚĞƐĞ ‘ŶŽŶ-ƌĞƐƉŽŶĚĞƌƐ ? show a decrease in VO2peak, or an increase within the test-retest 
variability of VO2peak measurement (generally accepted to be ±6%).
16 W18 The mechanisms driving this 
variability in A?VO2peak are not well understood, nor do we have good predictors for the response to 
exercise intervention. Possible contributing factors are summarized in Figure 1. As we are moving into 
an era of personalized medicine, and exercise therapy needs to be individually tailored in order to 
 
Figure 1: Known factors possibly influencing the response to exercise 
training. These factors are grouped as cardiac, non-cardiac, external and 
comorbidities. They possibly influence  baseline VO2peak and/or 
A?VO2peak, and are themselves determined by genetic, epigenetic, and 
environmental factors and drugs, nutrition and sex. CKD = chronic kidney 
disease, COPD = chronic obstructive pulmonary disease, VO2peak = peak 
ŽǆǇŐĞŶƵƉƚĂŬĞ ?A?sK2peak = relative change in VO2peak following exercise 
training. 
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generate the best response within the greatest safety margin, this is a field of research that requires 
urgent attention. 
 
One way of addressing this line of research is by performing 'secondary' responder analyses on 
existing datasets of original publications. This can be accomplished by quantifying the number of non-
responders and responders to different types of exercise interventions. For example, Williams et al. 
combined data from different laboratories that had compared training volumes ranging between high 
and moderate intensities, in populations of both healthy subjects and patients with established 
cardiovascular disease.19 When exercise was performed with great amounts and high intensities, the 
likelihood of subjects increasing their exercise capacity was significantly greater. Similarly, Montero et 
al. showed that healthy non-responders to an exercise training intervention did increase their VO2peak 
when subjected to greater training volumes.20 Yet, the evidence regarding the additional beneficial 
effects of higher exercise intensities is still conflicting.21 One could argue that the main determinant 
for improvements in exercise capacity is the total energy expenditure rather than the exercise 
intensity in these subjects. More comparative exercise intervention studies are needed to determine 
the inter-individual variability in exercise capacity caused by different types of exercise programs. 
 
It still remains to be elucidated which phenotypic and genotypic characteristics predict the response 
of a patient to these specific exercise interventions. Previous studies already suggested that in 
addition to exercise training characteristics (e.g. intensity, volume, type), common personal 
characteristics like age, sex, body mass index, and baseline physical fitness predict between 15-21% of 
variability in A?VO2peak.13,15,17,19 Moreover, an additional physiological factor that may influence 
A?VO2peak in patients with chronic heart failure (HF) is the circulatory response to acute exercise.22,23 
Considering the relatively low predictability of these factors, other more important factors that affect 
A?VO2peak likely still need to be discovered. 
 
Heritability explains more than 50% of the inter-individual differences in cross-sectionally measured 
VO2peak.
24,25 In addition, the Heritage Family study demonstrated that the change in VO2peak to 
exercise training intervention is also largely (47%) determined by heritable factors (i.e. genetic, 
epigenetic or familial environmental factors).26 Heritability of training-induced changes in 
haemodynamic response and skeletal muscle characteristics are also relatively high.27,28 Most 
importantly, the heritability of A?VO2peak was independent of baseline VO2peak.29 This implies that 
even subjects with a low aerobic capacity may still substantially benefit from exercise training during 
CR.  
 
Previous research has used several approaches to improve our understanding of the genetics 
underlying the variability in VO2peak and A?VO2peak. In the late 1990s Montgomery et al. assessed left-
ventricular wall thickness as a proxy for the response to exercise intervention in 140 army recruits.30 
Subjects with a specific mutation in the gene for the angiotensin converting enzyme showed no 
improvement in left ventricular mass, while in subjects without this mutation left ventricular mass 
increased by 22-26%. After this publication,  ‘The human gene map for performance and health-
related fitness phenotypes ? was created.31 Even though more than 200 autosomal gene variants and 
quantitative trait loci have been identified from this study, the authors noted that data was mainly 
derived from underpowered sample sizes. Therefore this study did not provide compelling evidence 
that DNA sequence variants in a given gene are associated with human variation in fitness and 
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performance traits.31 Interaction between gene variants and disease modifying factors add to the 
complexity. For example, a single nucleotide polymorphism (SNP) in the FTO gene is associated with 
higher risk for adiposity, but this interaction term was weaker in physically active people.32 
 
A means to overcome the focus on a single gene or locus could be transcriptome wide RNA expression 
profiling studies. Timmons et al. identified 11 SNPs in skeletal muscle, which were responsible for 
nearly 50% of the heritability of A?VO2peak in healthy subjects.33 Genome-wide association studies 
could also provide unbiased insight into the genetics underlying baseline VO2peak as well as 
A?VO2peak. Bouchard et al. discovered a total of 39 SNPs significantly associated with A?VO2peak.34 
Unfortunately, there was no overlap between the genes identified by Timmons et al. and those 
reported by Bouchard et al.35 Another large genome-wide association study compared SNPs in 1520 
elite athletes with SNPs in 2760 non-athletes, and identified only a single SNP (in the GALNTL6 gene) 
that was more common in athletes.36 Hence, while previous studies have started to use hypothesis-
free methods to improve our understanding of the genetics underlying VO2peak and A?VO2peak, there 
is still a long way to go. 
 
Post-translational modifications may also influence protein function. Indeed, several non-coding RNA 
species have been linked to VO2peak or A?VO2peak. In healthy subjects, microRNAs are released into 
the circulation even after acute exercise, and exercise training induces long-term changes in their 
expression.37,38 In a rat model of HF, Souza et al. identified a set of 14 cardiac microRNAs of which 
expression was influenced by exercise training.39  Other studies have identified additional exercise-
responsive microRNAs in animal models of different cardiovascular diseases.38 To date, only two small 
studies have assessed the effect of exercise training on microRNA expression in human patients with 
established cardiovascular disease.40,41 Taurino et al. showed that miR-92a and miR-92b were 
upregulated after exercise-based CR in patients with coronary artery disease, coinciding with a 
downregulation of their gene targets.40 Xu et al. identified 3 miRNA dysregulated by acute exercise in 
HF patients, but a clear correlation with VO2peak was not found.
41 More extensive studies, including 
larger numbers of patients and screening for more miRNA, are still needed before reliable conclusions 
can be drawn. 
 
Personalization of therapy also means that target parameters need to be chosen according to the 
clinical need of the patient, based on their underlying morbidities and risk profile. This is not 
necessarily always VO2peak, but can be improved submaximal exercise parameters, increased cardiac 
function, better glucose handling, reduced inflammation, or improved vascular stiffness.42 W46 Of note, 
target parameters of the exercise intervention might even change over time in each patient. 
 
¾ To summarize, the change in VO2peak to exercise training shows large inter-individual 
variability. Understanding how such inter-individual differences emerge is important, as a 
lower response is linked to poorer outcomes. ѐVO2peak seems to be regulated by the 
interaction between heritable factors and lifestyle  ? including exercise parameters, SNPs, and 
non-coding RNAs  ? but individual targets have yet to be confirmed. We need controlled 
randomized studies using multi-omics techniques (transcriptomics, genomics, proteomics and 
metabolomics) ƚŽŝĚĞŶƚŝĨǇƉŽƚĞŶƚŝĂůƉĂƚŚǁĂǇƐŝŶĂ ?ƐǇƐƚĞŵƐďŝŽůŽŐǇ ?ĂƉƉƌŽĂĐŚ ?The complex 
interaction between lifestyle and heritable factors likely explains a large part of the individual 
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response to exercise training, and future studies should aim to improve our understanding of 
this interaction. 
2.2 The potential role of sex differences in response to   
In general, VO2peak is ~15% lower in women compared to men.
47 Intriguingly, however, women seem 
to experience better clinical outcomes following exercise training, despite similar improvements in 
exercise capacity.48,49 While sex-specific effects thus likely play a key role in the clinical benefits 
associated with exercise interventions, the mechanisms responsible for these benefits remain poorly 
understood. 
Cardiac physiology as well as pathophysiology are markedly different between men and women. The 
main differences are summarized in Table 1. For a more extensive overview, we refer the reader to 
existing reviews.50 W52 
 
Table 1: Selected sex differences in cardiac physiology and pathophysiology 
Subject Sex difference Ref. 
Epidemiology: 
risk factors 
Premenopausal women have lower blood pressure compared to men, 
which is lost after menopause 
53 
When present, risk factors (hypertension, cholesterol levels, diabetes) 
are more often uncontrolled in women 
54 W57 
Epidemiology: 
cardiac disease 
Epicardial coronary artery disease is less common in women   58 
Heart failure: higher prevalence of preserved EF in women and of 
reduced EF in men 
59 
Acute coronary syndromes: in women more often due to spontaneous 
coronary artery dissection, Takotsubo syndrome, and microvascular 
angina 
60,61 
Cardiovascular 
structure and 
function 
LV volumes are smaller in women, even after adjustment for body size 62 
LV EF is higher in women and the increase in EF with age is larger in 
women 
63 
Reduction in LV systolic long axis contraction with age is larger in 
women 
64 
Increased vascular and LV stiffness in women 62 
Cardiomyocyte 
function 
Ion handling and rhythmicity differs in women, leading to higher rest 
heart rate, shorter PR and longer QT segments  
65,66 
Altered calcium handling in female cardiomyocytes, myofibrils require 
more time to relax 
67 
Female cardiac mitochondria suffer less oxidative damage under stress 68 
Cardiomyocytes have higher protein kinase A activity in women 69 
Cardiomyocyte loss with ageing is higher in women 70 
Response to 
treatment 
Women show higher mortality after coronary revascularization and 
cardiac surgery 
71,72 
Response to cardiac resynchronization therapy may be better in women 73 
Abbreviations: EF = ejection fraction, LV = left ventricular  
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Sex-specific hormones may explain part of these differences. In pre vs. postmenopausal women of 
similar age, blood pressure is lower, and left ventricular end-systolic volume, ejection fraction and 
filling rate are larger.74 The vasodilating properties of oestrogen may play a role.75 Also, RNA 
sequencing in cardiomyocytes revealed more than 600 genes with sexually dimorphic expression 
patterns.69 This adds to genetic differences due to male specific Y-chromosomal gene expression and 
differences in epigenetics (histone and DNA modifications, non-coding RNA expression).52 
Thus, in addition to the obvious endocrine differences between men and women, a variety of 
anatomical, genetical and molecular differences exists within the heart. These may influence not just 
cardiovascular disease progression, but also affect secondary prevention strategies. 
 
While central hemodynamic differences likely explain some of the sex-specific effects in response to 
CR,50 other factors are also involved. It is well established that cardiac disorders induce secondary 
impairments to the periphery, including endothelial and skeletal muscle dysfunction, which are closely 
linked to symptoms of exercise intolerance and prognosis.76 Surprisingly, it is still largely unclear how 
sex modulates the crosstalk of mechanisms governing the loss of endothelial, skeletal and cardiac 
function. A few studies have revealed that in patients with HF, mitochondrial enzymes in skeletal 
muscle show either no major changes or more pronounced deficits in men compared to women, with 
a greater shift towards glycolytic enzymes and type IIX fatigable fibres in men.77,78 In response to an 
aerobic endurance training intervention, evidence has revealed minor differences in terms of skeletal 
muscle biochemistry, with reports suggesting men with HF can increase the content of the slow 
myosin heavy chain isoform towards similar levels to that observed at baseline in women.79 Thus, 
women may experience a greater preservation of muscle oxidative function compared to men with 
HF, which could help to explain why women demonstrate greater clinical benefits after CR.48 The 
mechanisms underpinning the sex-specific differences in muscle physiology and effects of exercise 
intervention remain unclear. Hormonal effects of oestrogen regulation on mitochondrial dynamics 
and/or a preferential shift towards fatty acid oxidation in women may play a role, 80,81 but more 
extensive measures of muscle function and physiology and higher sample sizes are still required to 
confirm this.  
 
In addition to skeletal muscle alterations, endothelial dysfunction also develops in HF patients, both in 
men and women.82 Yet little data is available to clearly demonstrate whether any sex-specific 
alterations are present following CR in patients. Recent evidence from animals models of HF have 
shown that high-intensity interval training can attenuate endothelial dysfunction in both female and 
male rats, which seems to act via mechanisms specifically lowering oxidative stress in males and 
increasing endothelial nitric oxide synthase expression in females.83,84 Whether these molecular 
benefits are paralleled in male and female patients with HF remains unclear.  Furthermore, sex-
specific substrate utilisation could play a key role in the exercise response in women and may fill the 
above-mentioned gap in the literature with regards to the effectiveness of exercise-based CR. One 
example is that women rely on carbohydrates to a lesser extent but have a higher content of 
intramyocellular lipids.85 
 
While CR programs clearly reduce the risk of all-cause and cardiac-related mortality and improve 
quality of life, directly extrapolating these findings from men to women remains fraught with 
complexities since women have consistently been under-represented in previous trials.86 In large 
meta-analyses and randomized controlled trials, the amount of women recruited was 11-28%.50 Given 
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that women are also ~40 % less likely to enrol in CR and have a significantly lower adherence to the 
interventions compared to men, 87,88 the need to better understand sex-specific mechanisms in 
response to exercise training will first require rapid improvement in CR recruitment and adherence of 
women. Identification of sex-specific targets is likely to substantially improve outcomes following CR 
programmes by optimising training regimes. 
Nonetheless, women seem to benefit at least as much from exercise-based CR as men.48,89,90 The most 
recent Cochrane reviews which assessed the benefits of exercise-based CR concluded that exercise 
improves cardiovascular mortality and hospitalization (in patients with coronary artery disease) and 
improves ŚĞĂůƚŚ ?ƌĞůĂƚĞĚƋƵĂůŝƚǇŽĨůŝĨĞ (in patients with coronary artery disease or HF).91,92 The authors 
also clearly state that evidence for benefits of exercise-based CR in women is currently insufficient. 
Given the above mentioned physiological and pathophysiological differences between men and 
women, we cannot assume that exercise regimes which worked for men will also be effective for 
women.  
 
¾ To summarize, important differences exist in the response to CR in men and women. Besides 
obvious differences in cardiovascular and skeletal muscle structure, function and physiology, the 
underlying hormonal and molecular mechanisms are still understudied. Identification of sex -
specific targets might further improve outcomes after CR. 
2.3 Immune-metabolism interactions and inflammation 
Both enhanced activation and impaired resolution of inflammation are major underlying principles of 
cardiovascular and metabolic pathologies.93 Regular exercise training has been shown to lower 
systemic and vascular inflammatory load within a few weeks of intervention.46 This has been partly 
attributed to active secretion of anti-inflammatory myokines from skeletal muscle.94 While 
biochemical interactions of some myokines have been deciphered, it remains a major task to chart the 
network of biochemical interactions between energy demand by skeletal muscle contractile activity 
(affected by exercise parameters, such as duration, type and frequency) and the fine-tuning of 
inflammatory mechanisms. The recent years have brought a refinement in our understanding of 
inflammation in atherosclerosis, including the appreciation of resolution of inflammation as an active 
process, distinct from inhibition of inflammation, as well as the tight interactions between immune 
cell activation and their energy metabolism. Only a fraction of these newly understood mechanisms 
has been exploited in the context of the cardiovascular effects of regular exercise training. 
 
Resolution of inflammation versus anti-inflammation: The inability to resolve an ongoing inflammatory 
process is a hallmark of inflammatory degenerative processes, including atherosclerosis. On the one 
hand, innate immune-activating signals - ligands of pattern-recognition receptors, such as modified 
lipids - do not disappear in atherosclerosis, as it would happen in a  ‘normal ? injury. On the other hand, 
the production of pro-resolving mediators appears to be dysregulated. Anti-inflammatory therapies 
have been employed more or less successfully in secondary cardiovascular prevention. However, 
therapeutic success appears to depend on the inflammatory signalling mechanism targeted, likely 
interleukin-1E and interleukin-6 signalling, and may be flawed by increased incidence of lethal 
infections.95,96 In addition, blocking inflammation also appears to block resolving mechanisms, the 
removal of apoptotic particles and cell debris as well as the induction of regenerative processes. 97  
The termination of an acute inflammatory response is normally governed by both the decay of pro-
inflammatory signals, as well as the active production of pro-resolving factors.98 A number of studies 
 10 
support the ability of exercise - ranging from a single session of high-intensity interval exercise to a 3-
month multicomponent exercise programme  W to reduce cellular responsiveness to toll-like receptor -
mediated signalling, induced by damage-associated molecular patterns.99 W101  
Dietary interventions targeting synthesis of specialized resolving mediators (SPM) have been tested 
for some time now and it becomes evident that both, the dosage and the formulation might be 
relevant to their success in cardiovascular prevention.102 In contrast, only few studies have 
systematically addressed the effects of exercise intervention on the release of SPMs  W resolvins, 
lipoxins, protectins and maresins  W but the existing literature indicates an increase in SPM release by 
regular exercise.103 W105 This might be attributed to acute and chronic effects: strain and acute release 
of pro-inflammatory mediators are associated with SPM release in acute high-intensity exertion, while 
chronic effects of exercise intervention might be connected to the exercise-mediated shift in 
macrophage polarization towards the M2-like phenotype.103,105,106 M2-like macrophages are better 
suited to perform efferocytosis than the M1-like phenotype and it is during efferocytosis that SPMs 
are released.107 Thus, we know that regular exercise is associated with a shift towards the more pro-
resolving macrophage spectrum, as well as higher levels of pro-resolving mediators, but we do not 
know which exercise parameters (e.g. intensity, volume, type) could be used to boost this effect, nor 
whether a combination with dietary approaches to supplement SPMs could potentiate the effects of 
exercise intervention on cardiovascular inflammation (Figure 2).  
 
Energy metabolism and inflammation: From tumour biology, we know that increased glycolysis and 
glutaminolysis provide energy flexibility to the cell and generate intermediates that feed into anabolic 
processes - probably the reason why glycolysis is preferred over oxidative phosphorylation by 
proliferating tumour cells.108 W110 In a similar manner, glycolysis is preferred by activated and 
proliferating myeloid and lymphoid cells111 and stimulating glycolysis can activate macrophages.112 In 
addition, M1-type macrophages feature a  ‘broken ? Krebs cycle, with increased output of intermediates 
that serve as substrates in the synthesis of pro-inflammatory mediators, or are pro-inflammatory 
 
Figure 2: Known and unknown interactions between exercise, nutrition and pro-resolving 
macrophage polarization and function in cardiovascular disease. CVD = cardiovascular disease, 
DAMP = damage-associated molecular patterns. 
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mediators in themselves.113 114,115 In contrast,  ‘alternative ? M2-like macrophages favour oxidative 
phosphorylation and fatty acid oxidation.116,117 Indeed, oxidative phosphorylation was a prerequisite of 
M2-type phenotypic macrophage polarization.117  
Of note, the complex spectrum of M2-like macrophage phenotypes recognized with their diverse roles 
in atherosclerosis, have not been charted in detail for their inflammation-resolving and energy 
metabolism phenotype yet, nor regarding the effect of exercise in their polarization. Similarly, NK cells 
and various T lymphocyte populations react to acute and chronic exercise and contribute to both, 
polarization of innate immune cells and functionality of various tissues and organs, including distinct 
fat depots (perivascular, subcutaneous, visceral).118 
 
Both the amount and type of energy substrates provided and physical exercise can affect the 
phenotype of monocytes and macrophages.112,119 W122 Energy sensors, such as AMP-dependent kinase , 
can be targeted by both diet and exercise. On the way to personalized lifestyle-based therapies, we 
need to learn more about the integration of exercise parameters (e.g. type, intensity, frequency, 
volume) with diet (e.g. macronutrient composition, amount and timing of eating/fasting) and 
pharmacological means to modulate energy metabolism and (thereby) activation state of 
inflammatory cells.123 W127 Of note, activation of the relevant mechanisms might shift between 
individuals, being influenced by a number of factors such as hormonal status/sex, age, 
pharmacotherapy and co-morbidities as well as genetic background.128 W130 
 
¾ To summarize, macrophage phenotype shift, leading to reduced release of pro-inflammatory 
mediators and an increased release of pro-resolving mediators, might well be a nexus of exercise-
mediated anti-inflammatory and metabolic cardio-protective effects. The available seminal data, 
however, requires a better resolution: continuously improved techniques of single-cell immuno-
phenotyping131 and assessment of cellular metabolism132 allow for the fine-mapping of immune-
inflammatory interactions and can be used to develop diagnostic tools, assessing individual 
response to exercise and personalizing exercise parameters. In addition, better understanding of 
the cellular and molecular nodes of the immuno-metabolic network might help to optimize 
exercise parameters on an individual level to improve cardio-vascular and metabolic benefit, 
potentially in combination with pharmacological and diet-based approaches. 
 
 Challenges and opportunities in translational CR research methodology  
The advent of high-throughput molecular techniques, single-cell diagnostics and organs-on-a-chip 
have opened countless opportunities in exercise research, but some important challenges have 
surfaced simultaneously. How can we successfully pinpoint important findings within these vast 
datasets? And if computers can handle increasingly complex tasks, what is the use of animal models in 
the future?  
3.1 Impact of  ?big dĂƚĂ ?and artificial intelligence  translational research in CR  
As analytical techniques evolve, new challenges arise with regards to handling the enormous amount 
of data they generate. This is especially true in the area of genomics, epigenomics, proteomics and 
metabolomics, but also applies to datasets obtained from large clinical trials or registries, and 
epidemiological research.133 These datasets cannot be readily viewed on any computer, which 
ĐŽŵƉůŝĐĂƚĞƐŚƵŵĂŶƉĂƚƚĞƌŶƌĞĐŽŐŶŝƚŝŽŶ ?DŽƌĞŽǀĞƌ ?ƚŚĞĂŶĂůǇƐŝƐŽĨ ‘ďŝŐĚĂƚĂ ?ƌĞƋƵŝƌĞƐĂĚĚŝƚŝŽŶĂů
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ƐƚĂƚŝƐƚŝĐĂůƉƌĞĐĂƵƚŝŽŶ ?ƚĂŬŝŶŐŝŶƚŽĂĐĐŽƵŶƚƚŚĞŝŶĐƌĞĂƐĞĚ ‘ŶŽŝƐĞ ?ŽĨŚŝŐŚ-throughput techniques.134 
EŽǀĞů ‘ĚĂƚĂŵŝŶŝŶŐ ?ƚĞĐŚŶŝƋƵĞƐŚĂǀĞďĞen developed to derive relationships and statistical inference 
from these datasets, often relying on some form of artificial intelligence. These techniques, grouped 
ƵŶĚĞƌƚŚĞƚĞƌŵ ‘ŵĂĐŚŝŶĞůĞĂƌŶŝŶŐ ? ?ĐĂŶďĞĞŝƚŚĞƌƐƵƉĞƌǀŝƐĞĚ ?ƚŚĞƵƐĞƌĚĞƚĞƌŵŝŶĞƐƚŚĞƌĞůĂƚŝon 
between subjects) such as traditional regression analysis, or unsupervised (the computer determines 
the relation between subjects), such as clustering analysis.135,136 
 
Some of these novel techniques have already been applied to translational exercise research. In 2009, 
Goud et al. set up a cluster-randomized trial in 21 CR centres, comparing effects of a computerized 
decision support system to standard care.137 In centres implementing the decision support system, 
concordance with CR guideline recommendations were modestly increased, reducing both over- and 
under-treatment. Further efforts have been made with regard to artificial intelligence-based exercise 
prescription.138 W142 Most of these studies describe a framework to automate exercise prescription 
based on patient demographics, comorbidities, test results and reason for referral. Randomized 
clinical trials evaluating these fully computerized exercise prescription are still lacking. 
Finally, the vast amount of data obtained from wearable devices opens up possibilities for data-driven 
personalization strategies. For example, one study succeeded in predicting active energy expenditure 
(a predictor of A?VO2peak) from photo-plethysmographic heart rate measurements, even in patients 
under beta blocker therapy.143 
 
But many more possibilities of  ‘big data ? and machine learning exist in the field of CR, which we will 
demonstrate at the hand of two examples from other areas within cardiovascular research: imaging 
and phenotyping. 
Imaging is especially suited for the application of machine learning because images contain a rich 
amount of data both within the image itself and through extraction of quantitative features.135 
Furthermore, powerful computational approaches to handle image data have undergone extensive 
development within academic clinical research and non-medical fields such as facial recognition and 
image searching. 144 Combined with recent availability of large imaging datasets,145 this has meant 
artificial intelligence approaches to identify images, automatically quantify image features and predict 
disease from the patterns in the image have developed rapidly within cardiology and radiology.135 As a 
result, automated quantification is now entering clinical use, but broader diagnostic application will 
require robust clinical validation before adoption.146 Of particular interest in CR will be to understand 
whether imaging after cardiac events (e.g. echocardiography) contains information of value for 
prediction of outcome, risk of HF and likelihood of response to exercise interventions. 
 
Another approach of unsupervised machine learning is to find clusters of similar data items: subjects 
in the same cluster are similar to each other, and dissimilar to subjects in other clusters. This can aid in 
discovering subtypes of patients with a certain disease. For example, machine learning has been able 
to identify clusters of patients with HF based on their baseline characteristics and test results 
(including cardiopulmonary exercise tests).147 W150 Phenotyping through machine learning predicted the 
prognosis of HF patients, and performed better compared to traditional predictors such as ejection 
fraction.149 
 
A major concern ŽĨĂƌƚŝĨŝĐŝĂůŝŶƚĞůůŝŐĞŶĐĞŝƐƚŚĞ ‘ďůĂĐŬďŽǆ ?ƉŚĞŶŽŵĞŶŽŶ ?DŽƌĞĐŽŵƉůĞǆmachine 
learning processes, such as neural networks, build layer upon layer of automated decisions up to a 
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point where it is impossible to retrace the individual steps.151 Thus, while some neural networks have 
been proven to outperform humans (for example in image recognition152), it is often hard to assess 
how the computer reached its decision or classification. KŶĞƚĞĐŚŶŝƋƵĞƚŽŽǀĞƌĐŽŵĞƚŚĞ ‘ďůĂĐŬďŽǆ ?ŝƐ
ƚŽĂƐŬƚŚĞĐŽŵƉƵƚĞƌƚŽƐŝŵƵůƚĂŶĞŽƵƐůǇĐƌĞĂƚĞĂƐŝŵƉůĞƌ ‘ƐƵƌƌŽŐĂƚĞ ?ŵŽĚĞůƚŽŐĂŝŶŝŶƐŝŐŚƚŝŶƚŚĞ
reasoning process.153 
Also, while the decision process can be fully automated and intelligent, large datasets still need to be 
imputed to train machine learning models. Availability of enough training data is currently still an 
issue, but the increased promotion of open science and data sharing will hopefully provide an answer 
to this problem soon. 
Finally, a major challenge will be to convert artificial intelligence-derived predictions and 
recommendations into effective action. Better phenotyping and improved risk stratification do not 
automatically lead to improve health. To truly achieve a health care transformation, behavioural 
changes are needed at both patient and physician level.154 For example, artificial intelligence may 
ŝŵƉƌŽǀĞĞǆĞƌĐŝƐĞƉƌĞƐĐƌŝƉƚŝŽŶ ?ďƵƚĂƉĂƚŝĞŶƚ ?ƐŚĞĂůƚŚǁŝůůŽŶůǇŝŵƉƌŽǀĞŝĨŚŝƐŽƌŚĞƌƉŚǇƐŝĐŝĂŶ
implements this improved prescription in practice, and he or she adheres to the prescribed training. 
 
¾ To summarize, early applications in CR research and advanced examples from imaging and 
phenotyping studies show that the advent of  ?big data ? and machine learning will likely change 
current practice. Major challenges include picking up useful signals between increased noise in 
big datasets, ƚŚĞ ?ďůĂĐŬďŽǆ ?ƉŚĞŶŽŵĞŶŽŶ ?ĂŶĚimplementing behavioural changes based on 
computerized recommendations. We suggest some future research areas in Table 2. 
 
Table 2: Suggested research areas for application of data mining and machine learning in exercise-
based CR 
Data Source Suggested Application Examples 
Cardiopulmonary 
exercise test raw data 
Improve risk stratification Discover novel prognostic 
variables 
Detection of subliminal patterns Exercise oscillatory ventilation 
Autonomic dysfunction 
Baseline data 
(including imaging) of 
large exercise studies 
Discover novel subtypes / phenogroups  Different phenotypes of heart 
failure 147 W150 
Improve diagnostic process AI-driven diagnosis of left 
ventricular dysfunction 
Outcome data of large 
exercise studies 
Improve prescription of CR AI-driven exercise prescription, 
similar to human-driven Expert 
tool 141,142 
Omics (genomics, 
epigenomics, 
proteomics, 
metabolomics) 
Prediction of low or high response to CR 
 
Presence of certain SNP 
indicates better response 33,34 
Improve prescription of CR Presence of certain SNP 
indicates better response to 
certain training modality  
AI = artificial intelligence, CR = cardiac rehabilitation, SNP = single nucleotide polymorphism 
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3.2 Sense and nonsense of animal models 
Appropriate animal models are important to unravel the molecular mechanisms for how exercise-
based CR mediates its beneficial effects. Small rodents in particular are attractive models for 
cardiovascular research, possessing unique properties such as easy handling, short gestation time and 
low costs. Perhaps most important is the availability of transgenic mice and rats, which allow the 
possibility to study the involvement of specific molecules in transmitting the positive effect of exercise 
training, which otherwise would not be possible in humans. Nevertheless, a certain scepticism is 
warranted based on whether animal models appropriately translate to humans, which has resulted 
(and rightly so) in the value of such research being questioned.155 W157 
 
An ideal disease model should mimic the human condition genetically, experimentally and 
physiologically. Therefore, using inbred mouse strains may not reflect the response generated in a 
genetically polymorphic human population, which may be one reason for the failure of many 
promising preclinical drugs when translated into human clinical trials. In support, a recently published 
comment stated that >80% of potential therapeutics fail when tested in humans, even after animal 
studies have provided evidence that the treatment is safe and effective.158 One future avenue to 
circumvent such translational problems may reside in the use of humanized models, whereby mice 
expressing human transgenes or engrafted human cells/tissue are used in preclinical research.159 
Obviously, generating diseased animal models due to genetic defects is much easier than trying to 
mimic a more complex disease pattern, where several comorbidities contribute to the final clinical 
phenotype. One contemporary example of such a complex disease is heart failure with preserved 
ejection fraction (HFpEF). Since the development of HFpEF is driven by several comorbidities, which 
include hypertension, diabetes, obesity and ageing,160 W162 it remains difficult to define an animal model 
that appropriately mimics the HFpEF phenotype. As of yet, the animal models used to probe molecular 
changes occurring in HFpEF and in response to exercise training have been predominantly based on a 
single risk factor such as aging or hypertension.83,163,164 More recently this line of research included a 
more clinically relevant animal model, in a way that HFpEF develops due to the onset of multiple 
comorbidities that mirror a metabolic syndrome.84,165 W167 Another problem with appropriate animal 
models may be that most models develop over a short time period, whereas in humans sometimes 
several years or decades pass before a clear phenotype is established. 
 
Animals used for cardiovascular exercise studies most commonly range from small rodents (e.g. mice, 
rats) to large animals (e.g. rabbits, canine, goats, sheep, pigs, horses).168 W173 In these animal models 
exercise can either be voluntary (e.g., animal cage is equipped with a running wheel) or forced (e.g., 
animal is placed onto a treadmill for a specific period). Many exercise training studies have been 
employed using a variety of animal models of diseases that include HF,165,174,175 diabetes,176,177 and 
neurodegenerative diseases.178 Beside the classical animal models (mouse and rat) used to analyse the 
effect of exercise training on molecular and physiological parameters, more recently other species 
have been used such as drosophila and zebrafish.179 W182 Exercise training in drosophila results in 
improvements of physiological and molecular measures, which include enhanced climbing speed, 
flight performance, aconitase levels, and cardiac contractility. Clearly, while the main advantage of 
using flies as an animal model is that you can train several thousand flies simultaneously, the question 
of whether and to what extent these findings translate to humans looms large. We also have to keep 
in mind that it is even more difficult in animal models to control for activity levels. In human studies 
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most of the patients recruited into an exercise study exhibit a very low exercise level, which is difficult 
to control for in animals.  
 
¾ To summarize, the  ?sense ? to use animal models to investigate the benefits associated with 
exercise in disease is difficult to refute: animal studies have often provided the initial clues to help 
elucidate how exercise exerts its benefits for treating disease. However, animal research can also 
provide much  ?nonsense ? when translated to humans. Future studies should therefore continue 
focusing on developing more complex and robust animal models of disease that closely reflect the 
human condition.  
 
 Conclusion and Outlook 
Exercise-based CR has consistently shown positive effects on the course of cardiovascular disease.  
However, recent studies showed that there is a large variation in training effects at the individual level, 
with up to one third of patients failing to demonstrate a significant increase in exercise capacity 
despite adequate compliance. Therefore, in order to improve the effects of exercise-based CR it is 
crucial to (1) gain more in-depth knowledge on the determinants and mechanisms governing the 
response to exercise in the organs - beyond the skeletal muscle, heart and vascular system - and (2) to 
acknowledge their interaction at a systemic level. 
Heritable and non-heritable factors each determine approximately 50% of inter-individual 
heterogeneity in A?VO2peak. High-throughput technologies in combination with improved bio-
informatics and bio-statistical approaches can help identify major regulatory nodes among large 
datasets that cannot be readily interpreted otherwise.  
Sex-specific differences in the response to exercise in cardiovascular therapy are severely 
understudied. Although endocrine, anatomical and molecular differences between men and women 
are assumed to play a role, the exact mechanisms remain largely unknown. Future research therefore 
needs to include sufficient numbers of female patients to address these issues.  
Based on these studies, a concise, easy-to-use panel of markers that could help personalize exercise 
parameters could be developed. This panel could include regulatory nodes identified in clusters of 
patients through their classical risk profile, but also inflammatory and metabolic status, and genetic 
traits identified through advanced bio-statistics. Finally, while animal models have inherent limitations 
complicating translation to humans, complex and robust animal models closely reflecting human 
cardiovascular diseases will be needed to test the hypotheses mentioned and to gain further insight in 
the complex physiology of exercise-based CR. 
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